For a long time, eosinophils were regarded as the central effector cells of asthma and were interpreted in the classical model as a direct damaging agent of the epithelium, as an amplifier of bronchial hyperresponsiveness and as the main driver of type 2-mediated airway inflammation. Scientific developments over the past two decades have differentiated, expanded and in some cases questioned this picture. Are eosinophils in fact primary culprits – or merely markers of more complex immunological patterns? A new Lancet publication sheds some light on this.
Autoren
- Tanja Schliebe
Publikation
- Asthma/COPD-Special
Related Topics
You May Also Like
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- From symptom to diagnosis
Dyspnea – pulmonary hamartomas
- Phobia
Propranolol and spider phobia: the time window is crucial
- Focus on prevention
Colorectal cancer screening – an update
- Rare diseases
Yellow nail and Swyer-James syndrome
- Contact eczema
Causes and prevention at work
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Diabetic ketoacidosis